 Brian Greffe
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 4 | 2021 | 333 | 0.430 |
Why?
| | Hepatoblastoma | 4 | 2022 | 27 | 0.420 |
Why?
| | Liver Neoplasms | 4 | 2022 | 507 | 0.320 |
Why?
| | Sarcoma, Ewing | 2 | 2021 | 65 | 0.260 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 97 | 0.250 |
Why?
| | Rhabdomyosarcoma | 2 | 2019 | 55 | 0.240 |
Why?
| | Wilms Tumor | 2 | 2018 | 69 | 0.230 |
Why?
| | Granuloma, Plasma Cell | 1 | 2003 | 11 | 0.220 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.190 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 23 | 0.190 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 80 | 0.190 |
Why?
| | Eye Neoplasms | 1 | 2021 | 16 | 0.180 |
Why?
| | Ribonuclease III | 1 | 2021 | 34 | 0.180 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 56 | 0.180 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 211 | 0.170 |
Why?
| | Protein C | 2 | 1989 | 45 | 0.170 |
Why?
| | Child | 23 | 2022 | 18348 | 0.160 |
Why?
| | Hodgkin Disease | 2 | 2016 | 120 | 0.160 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 62 | 0.150 |
Why?
| | Child, Preschool | 15 | 2021 | 9077 | 0.150 |
Why?
| | Adolescent | 23 | 2021 | 17806 | 0.150 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 385 | 0.150 |
Why?
| | Head and Neck Neoplasms | 2 | 2021 | 436 | 0.150 |
Why?
| | Survivors | 5 | 2016 | 411 | 0.140 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 126 | 0.140 |
Why?
| | Lung Diseases | 1 | 2003 | 696 | 0.140 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.140 |
Why?
| | Cytodiagnosis | 1 | 2017 | 29 | 0.140 |
Why?
| | Seminoma | 1 | 2017 | 17 | 0.140 |
Why?
| | Nuclear Proteins | 1 | 2021 | 592 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 584 | 0.130 |
Why?
| | Health Planning | 1 | 2015 | 46 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2022 | 706 | 0.120 |
Why?
| | Neoplasms | 3 | 2015 | 2105 | 0.120 |
Why?
| | Osteosarcoma | 2 | 2007 | 67 | 0.120 |
Why?
| | Abdomen, Acute | 1 | 1994 | 18 | 0.120 |
Why?
| | Transition to Adult Care | 1 | 2015 | 63 | 0.120 |
Why?
| | Male | 27 | 2021 | 55554 | 0.110 |
Why?
| | Survival Rate | 5 | 2019 | 1642 | 0.110 |
Why?
| | Sarcoma | 1 | 2015 | 138 | 0.110 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 212 | 0.110 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 16 | 0.110 |
Why?
| | Heart Diseases | 2 | 2016 | 330 | 0.110 |
Why?
| | Gene Rearrangement | 1 | 2013 | 138 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 115 | 0.100 |
Why?
| | Humans | 37 | 2022 | 114709 | 0.100 |
Why?
| | Infant | 12 | 2018 | 7932 | 0.100 |
Why?
| | Bone Marrow Transplantation | 3 | 2008 | 241 | 0.100 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.100 |
Why?
| | Embolectomy | 1 | 2011 | 11 | 0.100 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 227 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 1361 | 0.090 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2199 | 0.090 |
Why?
| | Female | 25 | 2021 | 59483 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2007 | 1895 | 0.090 |
Why?
| | Mutation | 1 | 2021 | 3349 | 0.090 |
Why?
| | Tumor Lysis Syndrome | 1 | 2010 | 7 | 0.090 |
Why?
| | Brain Neoplasms | 4 | 1999 | 984 | 0.080 |
Why?
| | Retrospective Studies | 9 | 2022 | 12511 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 181 | 0.080 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 86 | 0.080 |
Why?
| | Risk Assessment | 3 | 2015 | 2973 | 0.080 |
Why?
| | Cisplatin | 2 | 2010 | 263 | 0.080 |
Why?
| | SEER Program | 3 | 2016 | 196 | 0.080 |
Why?
| | Fetal Blood | 1 | 1989 | 270 | 0.070 |
Why?
| | Leiomyosarcoma | 2 | 1998 | 26 | 0.070 |
Why?
| | Receptors, Erythropoietin | 1 | 2007 | 22 | 0.070 |
Why?
| | Translocation, Genetic | 2 | 2021 | 94 | 0.070 |
Why?
| | Topotecan | 1 | 2007 | 10 | 0.070 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2007 | 66 | 0.070 |
Why?
| | Survival Analysis | 3 | 2018 | 1218 | 0.070 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2006 | 9 | 0.070 |
Why?
| | Adult | 14 | 2019 | 30542 | 0.070 |
Why?
| | Neuroblastoma | 2 | 2006 | 132 | 0.070 |
Why?
| | Carboplatin | 1 | 2006 | 135 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 179 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 2889 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 210 | 0.060 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2006 | 66 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1011 | 0.060 |
Why?
| | Primary Health Care | 1 | 2015 | 1514 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 382 | 0.060 |
Why?
| | Bone Neoplasms | 1 | 2007 | 194 | 0.060 |
Why?
| | Databases, Factual | 3 | 2018 | 1126 | 0.060 |
Why?
| | Neoplasms, Second Primary | 1 | 2006 | 94 | 0.060 |
Why?
| | Young Adult | 5 | 2018 | 10461 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2006 | 220 | 0.060 |
Why?
| | Incidence | 3 | 2007 | 2312 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2019 | 623 | 0.060 |
Why?
| | Stem Cells | 1 | 2008 | 546 | 0.060 |
Why?
| | Abdominal Abscess | 1 | 2003 | 24 | 0.060 |
Why?
| | Prognosis | 3 | 2021 | 3334 | 0.050 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2003 | 11 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2021 | 1122 | 0.050 |
Why?
| | Spinal Neoplasms | 1 | 2003 | 28 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 528 | 0.050 |
Why?
| | Recurrence | 2 | 2003 | 936 | 0.050 |
Why?
| | Infant, Newborn | 4 | 2016 | 5034 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2006 | 1270 | 0.050 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 17 | 0.050 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 17 | 0.050 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 21 | 0.050 |
Why?
| | Pneumothorax | 1 | 2021 | 40 | 0.050 |
Why?
| | Thyroid Diseases | 1 | 2000 | 30 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 130 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 334 | 0.040 |
Why?
| | Radiotherapy | 1 | 2021 | 176 | 0.040 |
Why?
| | Molecular Weight | 2 | 1989 | 331 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 305 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 11 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 994 | 0.040 |
Why?
| | Skull Neoplasms | 1 | 1998 | 22 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1176 | 0.040 |
Why?
| | Vincristine | 2 | 2010 | 100 | 0.040 |
Why?
| | Leiomyoma | 1 | 1998 | 44 | 0.040 |
Why?
| | Fluorouracil | 2 | 2010 | 152 | 0.040 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 24 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2017 | 50 | 0.040 |
Why?
| | Polymyositis | 1 | 1996 | 15 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 863 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 47 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2268 | 0.030 |
Why?
| | Middle Aged | 7 | 2017 | 26747 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2016 | 4420 | 0.030 |
Why?
| | Neutropenia | 1 | 1995 | 125 | 0.030 |
Why?
| | Aged | 4 | 2022 | 19078 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1053 | 0.030 |
Why?
| | Time Factors | 3 | 2018 | 6122 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 133 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 182 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1996 | 215 | 0.030 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1994 | 19 | 0.030 |
Why?
| | Fever | 1 | 1995 | 279 | 0.030 |
Why?
| | Klinefelter Syndrome | 1 | 1995 | 50 | 0.030 |
Why?
| | Laparotomy | 1 | 1994 | 96 | 0.030 |
Why?
| | Health Status | 1 | 1999 | 723 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2762 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2008 | 1086 | 0.030 |
Why?
| | Emergencies | 1 | 1994 | 146 | 0.030 |
Why?
| | Transcription Factors | 1 | 2021 | 1528 | 0.030 |
Why?
| | Program Development | 1 | 2015 | 342 | 0.030 |
Why?
| | United States | 3 | 2017 | 12175 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1635 | 0.030 |
Why?
| | Appendicitis | 1 | 1994 | 107 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1590 | 0.030 |
Why?
| | Physical Examination | 1 | 1994 | 220 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1843 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2249 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2099 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 1994 | 195 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 1226 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 313 | 0.030 |
Why?
| | Radiography | 1 | 1994 | 811 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 560 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 822 | 0.020 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2010 | 30 | 0.020 |
Why?
| | Hyperuricemia | 1 | 2010 | 44 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2010 | 103 | 0.020 |
Why?
| | Hyperkalemia | 1 | 2010 | 26 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 210 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1177 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1995 | 1477 | 0.020 |
Why?
| | Herpesvirus 4, Human | 2 | 1998 | 125 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 184 | 0.020 |
Why?
| | Thrombosis | 1 | 1989 | 297 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 291 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 82 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 71 | 0.020 |
Why?
| | Urogenital Neoplasms | 1 | 2006 | 5 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2006 | 90 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2010 | 526 | 0.020 |
Why?
| | Behavior | 1 | 2006 | 92 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4085 | 0.020 |
Why?
| | Rituximab | 1 | 2006 | 150 | 0.020 |
Why?
| | Hemorrhage | 1 | 2010 | 618 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 6346 | 0.020 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 59 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2006 | 333 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2010 | 524 | 0.010 |
Why?
| | RNA, Viral | 2 | 1998 | 566 | 0.010 |
Why?
| | Stereotaxic Techniques | 1 | 2003 | 29 | 0.010 |
Why?
| | Survival | 1 | 2003 | 37 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 2003 | 68 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2003 | 176 | 0.010 |
Why?
| | Immunotherapy | 1 | 2006 | 475 | 0.010 |
Why?
| | Morbidity | 1 | 2003 | 277 | 0.010 |
Why?
| | Motor Activity | 1 | 2006 | 640 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2006 | 769 | 0.010 |
Why?
| | Sleep | 1 | 2006 | 632 | 0.010 |
Why?
| | Hyperthyroidism | 1 | 2000 | 26 | 0.010 |
Why?
| | Thyroid Nodule | 1 | 2000 | 38 | 0.010 |
Why?
| | Hypothyroidism | 1 | 2000 | 65 | 0.010 |
Why?
| | Sella Turcica | 1 | 1998 | 13 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 43 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 156 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 61 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 2000 | 263 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1998 | 284 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1997 | 293 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 138 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1997 | 410 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 218 | 0.010 |
Why?
| | Prednisone | 1 | 1996 | 231 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 2 | 1998 | 3031 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1995 | 292 | 0.010 |
Why?
| | Pineal Gland | 1 | 1995 | 13 | 0.010 |
Why?
| | Anesthesia, Dental | 1 | 1974 | 19 | 0.010 |
Why?
| | Tooth Extraction | 1 | 1974 | 21 | 0.010 |
Why?
| | Anesthesia, General | 1 | 1974 | 45 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1996 | 450 | 0.010 |
Why?
| | Quality of Life | 1 | 2003 | 2356 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1996 | 1340 | 0.010 |
Why?
| | Cohort Studies | 1 | 2000 | 4899 | 0.010 |
Why?
| | Neutrophils | 1 | 1995 | 1163 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2003 | 9089 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 4621 | 0.000 |
Why?
| | Prospective Studies | 1 | 1995 | 6215 | 0.000 |
Why?
| | Risk Factors | 1 | 1995 | 8625 | 0.000 |
Why?
| | Oral Hemorrhage | 1 | 1974 | 3 | 0.000 |
Why?
| | Tachycardia | 1 | 1974 | 50 | 0.000 |
Why?
| | Angina Pectoris | 1 | 1974 | 63 | 0.000 |
Why?
| | Postoperative Care | 1 | 1974 | 219 | 0.000 |
Why?
| | Arrhythmias, Cardiac | 1 | 1974 | 278 | 0.000 |
Why?
| | Anticoagulants | 1 | 1974 | 547 | 0.000 |
Why?
|
|
Greffe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|